Lineage Cell Therapeutics (LCTX) EBITDA Margin Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) EBITDA Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136,290.00 |
| Dec 31, 2025 | 155,781.00 |
| Sep 30, 2025 | 107,491.00 |
| Jun 30, 2025 | 94,318.00 |
| Mar 31, 2025 | 101,399.00 |
| Dec 31, 2024 | 37,557.00 |
| Sep 30, 2024 | 138,375.00 |
| Jun 30, 2024 | 97,240.00 |
| Mar 31, 2024 | 91,382.00 |
| Dec 31, 2023 | 102,868.00 |
| Sep 30, 2023 | 51,656.00 |
| Jun 30, 2023 | 20,323.00 |
| Mar 31, 2023 | 146,014.00 |
| Dec 31, 2022 | 66,527.00 |
| Sep 30, 2022 | 40,633.00 |
| Jun 30, 2022 | 218,467.00 |
| Mar 31, 2022 | 325,985.00 |
| Dec 31, 2021 | 96,374.00 |
| Sep 30, 2021 | 36,163.00 |
| Jun 30, 2021 | -15,284.00 |